SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.38-9.0%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (6016)3/24/2002 11:35:42 AM
From: Biomaven  Read Replies (1) of 52153
 
Thanks, Miljenko - I hadn't seen those abstracts.

Folkman's original hypothesis was partly based on the fact that when you surgically remove primary tumors the remaining metastatic tumors tend to dramatically increase in size. Hence he figured that the primary tumor was secreting something that kept the mets in check, and endostatin was one such candidate.

These abstracts are somewhat consistent with that theory - continuing high levels of endostatin perhaps imply that the original tumor is still active. None of these abstracts look at the progression of the mets themselves based on endostatin level - something that would be interesting to see.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News